138 related articles for article (PubMed ID: 33439463)
1. Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra
Kim HS; Engel S; Neveu D; Thollot Y; Oster P; Yang K
Infect Dis Ther; 2021 Mar; 10(1):399-409. PubMed ID: 33439463
[TBL] [Abstract][Full Text] [Related]
2. Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years.
Yoo BW; Jung HL; Byeon YS; Han DK; Jeong NY; Curina C; Moraschini L; Kim SJ; Bhusal C; Pellegrini M; Miao Y
Hum Vaccin Immunother; 2020 Jun; 16(6):1260-1267. PubMed ID: 31634044
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
[TBL] [Abstract][Full Text] [Related]
4. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
5. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
6. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
Myers TR; McNeil MM; Ng CS; Li R; Marquez PL; Moro PL; Omer SB; Cano MV
Vaccine; 2020 Sep; 38(40):6291-6298. PubMed ID: 32747215
[TBL] [Abstract][Full Text] [Related]
7. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.
Hansen J; Zhang L; Klein NP; Robertson CA; Decker MD; Greenberg DP; Bassily E; Baxter R
Vaccine; 2017 Dec; 35(49 Pt B):6879-6884. PubMed ID: 28941623
[TBL] [Abstract][Full Text] [Related]
8. Safety of a quadrivalent meningococcal conjugate vaccine in healthy subjects aged 9 months to 55 years in Vietnam.
Phan CH; Nguyen TPT; Doan UY; Nguyen TA; Thollot Y; Nievera MC
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):515-520. PubMed ID: 30838704
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age.
Halperin SA; Baine Y; Domachowske JB; Aggarwal N; Simon M; Langley JM; McNeil SA; Friedland LR; Bianco V; Baccarini CI; Miller JM
J Pediatric Infect Dis Soc; 2014 Mar; 3(1):33-42. PubMed ID: 24567843
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
13. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.
Hansen J; Zhang L; Eaton A; Baxter R; Robertson CA; Decker MD; Greenberg DP; Bassily E; Klein NP
Vaccine; 2018 Apr; 36(16):2133-2138. PubMed ID: 29550195
[TBL] [Abstract][Full Text] [Related]
14. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
Hedari CP; Khinkarly RW; Dbaibo GS
Infect Drug Resist; 2014; 7():85-99. PubMed ID: 24729718
[TBL] [Abstract][Full Text] [Related]
15. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
Cutland CL; Nolan T; Halperin SA; Kurugol Z; Ahmed K; Perrett KP; Richmond P; Marshall HS; Ceyhan M; Kolhe D; Hezareh M; Van Der Wielen M
Vaccine; 2018 Mar; 36(14):1908-1916. PubMed ID: 29503112
[TBL] [Abstract][Full Text] [Related]
17. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
Neveu D; Mallett Moore T; Zambrano B; Chen A; Kürzinger ML; Marcelon L; Singh Dhingra M
Infect Dis Ther; 2023 Oct; 12(10):2367-2386. PubMed ID: 37755671
[TBL] [Abstract][Full Text] [Related]
18. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y
Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
